These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 17405837)

  • 1. Pharmacokinetics of recombinant methionyl human leptin after subcutaneous administration: variation of concentration-dependent parameters according to assay.
    Chan JL; Wong SL; Orlova C; Raciti P; Mantzoros CS
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2307-11. PubMed ID: 17405837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of subcutaneous recombinant methionyl human leptin administration in healthy subjects in the fed and fasting states: regulation by gender and adiposity.
    Chan JL; Wong SL; Mantzoros CS
    Clin Pharmacokinet; 2008; 47(11):753-64. PubMed ID: 18840030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.
    Lee JH; Chan JL; Sourlas E; Raptopoulos V; Mantzoros CS
    J Clin Endocrinol Metab; 2006 Jul; 91(7):2605-11. PubMed ID: 16636130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leptin hormonal kinetics in the fed state: effects of adiposity, age, and gender on endogenous leptin production and clearance rates.
    Wong SL; DePaoli AM; Lee JH; Mantzoros CS
    J Clin Endocrinol Metab; 2004 Jun; 89(6):2672-7. PubMed ID: 15181040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant methionyl human leptin administration activates signal transducer and activator of transcription 3 signaling in peripheral blood mononuclear cells in vivo and regulates soluble tumor necrosis factor-alpha receptor levels in humans with relative leptin deficiency.
    Chan JL; Moschos SJ; Bullen J; Heist K; Li X; Kim YB; Kahn BB; Mantzoros CS
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1625-31. PubMed ID: 15613409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant methionyl human leptin administration to achieve high physiologic or pharmacologic leptin levels does not alter circulating inflammatory marker levels in humans with leptin sufficiency or excess.
    Chan JL; Bullen J; Stoyneva V; Depaoli AM; Addy C; Mantzoros CS
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1618-24. PubMed ID: 15613407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic use of recombinant methionyl human leptin.
    Vatier C; Gautier JF; Vigouroux C
    Biochimie; 2012 Oct; 94(10):2116-25. PubMed ID: 22464954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating melanin-concentrating hormone, agouti-related protein, and alpha-melanocyte-stimulating hormone levels in relation to body composition: alterations in response to food deprivation and recombinant human leptin administration.
    Gavrila A; Chan JL; Miller LC; Heist K; Yiannakouris N; Mantzoros CS
    J Clin Endocrinol Metab; 2005 Feb; 90(2):1047-54. PubMed ID: 15546902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients.
    Musso C; Cochran E; Javor E; Young J; Depaoli AM; Gorden P
    Metabolism; 2005 Feb; 54(2):255-63. PubMed ID: 15690321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial.
    Zelissen PM; Stenlof K; Lean ME; Fogteloo J; Keulen ET; Wilding J; Finer N; Rössner S; Lawrence E; Fletcher C; McCamish M;
    Diabetes Obes Metab; 2005 Nov; 7(6):755-61. PubMed ID: 16219020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. r-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humans.
    Brennan AM; Lee JH; Tsiodras S; Chan JL; Doweiko J; Chimienti SN; Wadhwa SG; Karchmer AW; Mantzoros CS
    Eur J Endocrinol; 2009 Feb; 160(2):173-6. PubMed ID: 19029226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation and quantification of endogenous and recombinant-methionyl human leptin in clinical plasma samples by immunocapture/mass spectrometry.
    Wang Y; Heilig JS
    J Pharm Biomed Anal; 2012 Nov; 70():440-6. PubMed ID: 22795822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic model to describe the lymphatic absorption of r-metHu-leptin after subcutaneous injection to sheep.
    McLennan DN; Porter CJ; Edwards GA; Brumm M; Martin SW; Charman SA
    Pharm Res; 2003 Aug; 20(8):1156-62. PubMed ID: 12948012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of human leptin in mice and rhesus monkeys.
    Ahrén B; Baldwin RM; Havel PJ
    Int J Obes Relat Metab Disord; 2000 Dec; 24(12):1579-85. PubMed ID: 11126209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men.
    Chan JL; Heist K; DePaoli AM; Veldhuis JD; Mantzoros CS
    J Clin Invest; 2003 May; 111(9):1409-21. PubMed ID: 12727933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation.
    Guettier JM; Park JY; Cochran EK; Poitou C; Basdevant A; Meier M; Clément K; Magré J; Gorden P
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):547-554. PubMed ID: 18076675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine and metabolic effects of physiologic r-metHuLeptin administration during acute caloric deprivation in normal-weight women.
    Schurgin S; Canavan B; Koutkia P; Depaoli AM; Grinspoon S
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5402-9. PubMed ID: 15531489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of age on uptake, serum half-life and bioavailability of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J mice.
    Lee DW; Leinung MC; Grasso P
    Regul Pept; 2008 Oct; 150(1-3):62-5. PubMed ID: 18455249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems.
    Novakovic ZM; Leinung MC; Lee DW; Grasso P
    Regul Pept; 2009 Apr; 154(1-3):107-11. PubMed ID: 19344673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male Swiss Webster mice: a study comparing the pharmacokinetics of oral delivery to intraperitoneal, subcutaneous, intramuscular, and intranasal administration.
    Lee DW; Leinung MC; Grasso P
    Regul Pept; 2010 Feb; 160(1-3):129-32. PubMed ID: 20026361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.